(Q37398037)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

Principles for designing future regimens for multidrug-resistant tuberculosis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

main subject

tuberculosis

0 references

multiple drug resistance

1 reference

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Charles Robert Horsburgh

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Helen McIlleron

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Patrick Phillips

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

9

Eric Nuermberger

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

2

Bern-Thomas Nyang'wa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Grania Brigden

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Philipp du Cros

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Francis Varaine

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Michael Rich

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Carole D Mitnick

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

Manica Balasegaram

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

English

0 references

publication date

25 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

Bulletin of the World Health Organization

4 March 2020

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

92

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

68-74

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.

4 March 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Linezolid for treatment of chronic extensively drug-resistant tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Delamanid for multidrug-resistant pulmonary tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Rapid evaluation in whole blood culture of regimens for XDR-TB containing PNU-100480 (sutezolid), TMC207, PA-824, SQ109, and pyrazinamide

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

The diarylquinoline TMC207 for multidrug-resistant tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Treatment of multidrug-resistant tuberculosis: evidence and controversies.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Side effects associated with the treatment of multidrug-resistant tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Regimens of less than six months for treating tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: a study of injectable use and toxicity in practice

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Clinical benefit of delamanid (OPC-67683) in the treatment of multidrug-resistant tuberculosis patients in China

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3865549

Resistance to second-line drugs in multidrug-resistant tuberculosis

2 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24391302

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Results of 2 or 3 secondary drug combinations in the retreatment of chronic pulmonary tuberculosis

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24391302

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2471/BLT.13.122028

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

PubMed publication ID

24391302

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24391302%20AND%20SRC:MED&resulttype=core&format=json